Karyopharm Therapeutics Inc. (KPTI) Financials

NASDAQ Currency in USD Disclaimer

$0.62

south_east -$0.02 (-2.97%)
Day's range
$0.6
Day's range
$0.66

KPTI Income statement / Annual

Last year (2023), Karyopharm Therapeutics Inc.'s total revenue was $146.03 M, a decrease of 7.03% from the previous year. In 2023, Karyopharm Therapeutics Inc.'s net income was -$143.10 M. See Karyopharm Therapeutics Inc.�s key income statements, including revenue, expenses, profit, and income.

Period FY-2023 FY-2022 FY-2021 FY-2020 FY-2019 FY-2018 FY-2017 FY-2016 FY-2015 FY-2014
Period Ended 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015 12/31/2014
Operating Revenue $146.03 M $157.07 M $209.82 M $108.09 M $40.89 M $30.34 M $1.61 M $154,000.00 $250,000.00 $229,000.00
Cost of Revenue $4.94 M $5.21 M $3.40 M $2.71 M $2.41 M $161.37 M $107.27 M $86.94 M $97.74 M $60.13 M
Gross Profit $141.09 M $151.86 M $206.42 M $105.38 M $38.49 M -$131.04 M -$105.67 M -$86.78 M -$97.49 M -$59.90 M
Gross Profit Ratio 0.97 0.97 0.98 0.97 0.94 -4.32 -65.84 -563.53 -389.98 -261.56
Research and Development Expenses $138.75 M $148.66 M $160.84 M $150.81 M $122.34 M $161.37 M $107.27 M $86.94 M $97.74 M $60.13 M
General & Administrative Expenses $131.88 M $145.40 M $143.85 M $126.42 M $0.00 $48.85 M $24.87 M $23.95 M $21.58 M $15.95 M
Selling & Marketing Expenses $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Selling, General & Administrative Expenses $131.88 M $145.40 M $143.85 M $126.42 M $105.42 M $48.85 M $24.87 M $23.95 M $21.58 M $15.95 M
Other Expenses $0.00 -$83,000.00 -$85,000.00 $206,000.00 -$50,000.00 -$33,000.00 -$81,000.00 $10,000.00 -$2,000.00 -$27,000.00
Operating Expenses $270.63 M $294.06 M $304.69 M $277.23 M $227.76 M $210.22 M $132.14 M $110.89 M $119.33 M $76.08 M
Cost And Expenses $275.57 M $299.28 M $308.09 M $279.94 M $230.17 M $210.22 M $132.14 M $110.89 M $119.33 M $76.08 M
Interest Income $10.94 M $2.36 M $582,000.00 $2.82 M $5.42 M $4.03 M $1.70 M $1.28 M $897,000.00 $97,000.00
Interest Expense $23.82 M $25.00 M $26.05 M $27.14 M $15.65 M $2.49 M $0.00 $0.00 $0.00 $1,000.00
Depreciation & Amortization $530,000.00 $621,000.00 $789,000.00 $972,000.00 $974,000.00 $735,000.00 $713,000.00 $717,000.00 $634,000.00 $323,000.00
EBITDA -$118.42 M -$139.31 M -$96.99 M -$167.85 M -$182.93 M -$175.15 M -$128.21 M -$108.72 M -$118.44 M -$75.45 M
EBITDA Ratio -0.81 -0.89 -0.47 -1.56 -4.5 -5.8 -81.33 -719.04 -476.3 -330.9
Operating Income Ratio -0.89 -0.91 -0.47 -1.59 -4.63 -5.93 -81.33 -719.04 -476.3 -331.21
Total Other Income/Expenses Net -$13.24 M -$22.72 M -$25.55 M -$24.11 M -$10.28 M $1.50 M $1.62 M $1.29 M $895,000.00 $69,000.00
Income Before Tax -$142.78 M -$164.92 M -$123.82 M -$195.96 M -$199.55 M -$178.38 M -$128.92 M -$109.44 M -$118.18 M -$75.78 M
Income Before Tax Ratio -0.98 -1.05 -0.59 -1.81 -4.88 -5.88 -80.32 -710.64 -472.72 -330.9
Income Tax Expense $323,000.00 $369,000.00 $268,000.00 $309,000.00 $40,000.00 $26,000.00 $63,000.00 $139,000.00 -$895,000.00 -$69,000.00
Net Income -$143.10 M -$165.29 M -$124.09 M -$196.27 M -$199.59 M -$178.41 M -$128.98 M -$109.58 M -$118.18 M -$75.78 M
Net Income Ratio -0.98 -1.05 -0.59 -1.82 -4.88 -5.88 -80.36 -711.54 -472.72 -330.9
EPS -1.25 -2.02 -1.65 -2.72 -3.22 -3.14 -2.81 -2.92 -3.32 -2.43
EPS Diluted -1.25 -2.02 -1.65 -2.72 -3.22 -3.14 -2.81 -2.92 -3.32 -2.43
Weighted Average Shares Out $114.22 M $81.87 M $75.22 M $72.04 M $61.96 M $56.78 M $45.90 M $37.52 M $35.62 M $31.14 M
Weighted Average Shares Out Diluted $114.22 M $81.87 M $75.22 M $72.04 M $61.96 M $56.78 M $45.90 M $37.52 M $35.62 M $31.14 M
Link